ProCE Banner Activity

KEYNOTE-052: 5-Yr Update of First-line Pembrolizumab in Cisplatin-Ineligible Advanced Urothelial Cancer

Slideset Download
Conference Coverage
With approximately 5 years of follow-up, KEYNOTE-052 reports continued durable antitumor activity with pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced/metastatic urothelial cancer, especially those with PD-L1 CPS ≥10.

Released: June 11, 2021

Expiration: June 10, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme